Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1998-7-21
|
pubmed:abstractText |
Inefficient retroviral-mediated gene transfer to human hematopoietic stem cells (HSC) and insufficient gene expression in progeny cells derived from transduced HSC are two major problems associated with HSC-based gene therapy. In this study we evaluated the ability of a murine stem cell virus (MSCV)-based retroviral vector carrying the low-affinity human nerve growth factor receptor (NGFR) gene as reporter to maintain gene expression in transduced human hematopoietic cells. CD34(+) cells lacking lineage differentiation markers (CD34(+)Lin-) isolated from human bone marrow and mobilized peripheral blood were transduced using an optimized clinically applicable protocol. Under the conditions used, greater than 75% of the CD34(+) cell population retained the Lin- phenotype after 4 days in culture and at least 30% of these expressed a high level of NGFR (NGFR+) as assessed by fluorescence-activated cell sorter analysis. When these CD34(+)Lin-NGFR+ cells sorted 2 days posttransduction were assayed in vitro in clonogenic and long-term stromal cultures, sustained reporter expression was observed in differentiated erythroid and myeloid cells derived from transduced progenitors, and in differentiated B-lineage cells after 6 weeks. Moreover, when these transduced CD34(+)Lin-NGFR+ cells were used to repopulate human bone grafts implanted in severe combined immunodeficient mice, MSCV-directed NGFR expression could be detected on 37% +/- 6% (n = 5) of the donor-type human cells recovered 9 weeks postinjection. These findings suggest potential utility of the MSCV retroviral vector in the development of effective therapies involving gene-modified HSC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
83-92
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9639503-Animals,
pubmed-meshheading:9639503-Gene Expression,
pubmed-meshheading:9639503-Gene Transfer Techniques,
pubmed-meshheading:9639503-Genes, Reporter,
pubmed-meshheading:9639503-Genetic Vectors,
pubmed-meshheading:9639503-Graft Survival,
pubmed-meshheading:9639503-Hematopoiesis,
pubmed-meshheading:9639503-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9639503-Hematopoietic Stem Cells,
pubmed-meshheading:9639503-Humans,
pubmed-meshheading:9639503-Leukocytes,
pubmed-meshheading:9639503-Mice,
pubmed-meshheading:9639503-Mice, SCID,
pubmed-meshheading:9639503-Receptors, Nerve Growth Factor,
pubmed-meshheading:9639503-Retroviridae
|
pubmed:year |
1998
|
pubmed:articleTitle |
Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny.
|
pubmed:affiliation |
SyStemix, Inc, Palo Alto, CA, USA. LCheng@Osiristx.com
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|